Abstract

 Recent, large, high-quality trials have demonstrated some benefits of dapagliflozin for the treatment of chronic kidney disease (most often in patients with Type II diabetes) as compared to placebo.
 Data describing the clinical effectiveness of dapagliflozin has identified both relative benefits and no differences compared to placebo in various measures of renal and cardiovascular health and function, as well as health care utilization, mortality and adverse events.
 A large proportion of the available data has been generated from the same randomized controlled trial that has recently been reported in multiple publications describing various patient subgroups and outcomes.
 No evidence was identified describing the cost-effectiveness of dapagliflozin for the treatment of patients with chronic kidney disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
